Leading cancer authorities in Australia on Thursday
released for public consultation the world's most robust set of clinical
practice guidelines, aimed at maximising the benefits and reducing the harms
associated with the Prostate Specific Antigen (PSA) test for prostate cancer;
the second most common male cancer worldwide.
If ratified, these new draft guidelines are expected to
inform international opinion and clinical practice regarding PSA testing, where
currently consensus is lacking and widespread confusion about best practice
Professor Mary Gospodarowicz, President of the Union of
International Cancer Control (UICC) welcomes the draft guidelines, saying: "The
current PSA test is not accurate enough for population screening, yet it
remains in widespread use. We need to focus on helping both patients and
healthcare professionals understand the risks and benefits of this test to
empower them to make more informed choices around screening. We applaud the
Australian cancer authorities for taking the lead in developing the strongest
set of clinical guidelines seen to date in prostate cancer; developed through a
truly multisectoral approach. We expect the final recommendations of this
review to clear the current confusions that exist around PSA testing."
Approaches to prostate cancer testing differ across the
world. Decision-making is complicated by the need to balance effective cancer
detection and care, with concerns about over-diagnosis and prostate cancer
treatment adverse side effects, including urinary incontinence, loss of sexual
potency in men treated by radiotherapy and bowel problems.
The new draft guidelines, developed under the auspices of
Cancer Council Australia's guidelines unit with funding from Prostate Cancer
Foundation of Australia (PCFA), address these risk/benefit concerns. Key
For men without a prostate cancer diagnosis or symptoms
that might indicate prostate cancer
- For men informed of the benefits and harms of screening who wish to undergo regular testing, offer PSA testing every two years from age 50 to age 69, and offer further investigation if the PSA is greater than 3.0 ng/mL.
- In asymptomatic men interested in undergoing testing for early diagnosis of prostate cancer, digital rectal examination is not recommended as a routine test in the primary care setting.
- Do not offer PSA testing to a man who is unlikely to live another seven years.
Offer evidence-based decisional support to men considering whether or not to have a PSA test, including the opportunity to discuss the potential benefits and risks of PSA testing before the decision to test is confirmed.
Active surveillance and watchful waiting
- Offer active surveillance to men with prostate cancer who meet all the following criteria:
PSA ≤ 20 ng/mL, clinical stage T1-2 and Gleason score 6.
- Advise men with potentially curable prostate cancer considering watchful waiting that their risk of developing more advanced prostate cancer and dying from it will be higher with watchful waiting than with immediate definitive treatment but that, in the medium to long term, watchful waiting is unlikely to diminish their wellbeing and quality of life.
Guidelines development panel
member and leading cancer epidemiologist Emeritus Professor Bruce Armstrong AM,
University of Sydney, noted that the draft guidelines did not recommend a
national screening program, in keeping with health policy worldwide. "The draft
guidelines are intended to inform the interactions
between men and their doctors, when a man might request a PSA test or his
doctor might offer one",said Professor Armstrong AM.
Released today for public consultation via a
globally-accessible wiki platform, the draft guidelines have been developed by
a broad-based Australian Expert Advisory Panel, which included general
practitioners, public health experts, urologists, pathologists,
patient support groups and allied health professionals. This is the
first time anywhere in the world that an expert advisory panel with all key
stakeholders and varying perspectives has come together for such a systematic
evidence-based review in this area of men's health.
Associate Professor Anthony Lowe, PCFA CEO comments:
"Crucial to the development of these new draft guidelines is that a wide
variety of stakeholders worked collaboratively to gain consensus. It means we
are able to make the most informed recommendations to date on the benefits and
harms of PSA testing, and the optimum time to initiate treatment to save
Following today's launch as part of the opening of the 2014
World Cancer Congress, health professionals and interested members of the
public from around the world are invited to review and comment on the draft
guidelines at: wiki.cancer.org.au/australia/Guidelines:PSATesting. Following
the consultation phase, the draft guidelines will be submitted to the National
Health and Medical Research Council of Australia for approval.